Becton, Dickinson and Company $BDX Shares Sold by Hantz Financial Services Inc.

Hantz Financial Services Inc. lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 7.8% during the third quarter, Holdings Channel reports. The firm owned 48,323 shares of the medical instruments supplier’s stock after selling 4,094 shares during the quarter. Hantz Financial Services Inc.’s holdings in Becton, Dickinson and Company were worth $8,650,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in BDX. Moneco Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 2.6% in the 3rd quarter. Moneco Advisors LLC now owns 2,071 shares of the medical instruments supplier’s stock valued at $371,000 after purchasing an additional 52 shares during the period. Brown Lisle Cummings Inc. grew its stake in Becton, Dickinson and Company by 9.2% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock worth $97,000 after buying an additional 54 shares during the last quarter. Pension & Wealth Management Advisors Inc. increased its position in Becton, Dickinson and Company by 12.3% during the third quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock worth $94,000 after buying an additional 56 shares during the period. Brighton Jones LLC increased its position in Becton, Dickinson and Company by 0.7% during the third quarter. Brighton Jones LLC now owns 8,942 shares of the medical instruments supplier’s stock worth $1,601,000 after buying an additional 58 shares during the period. Finally, Elevation Point Wealth Partners LLC lifted its stake in Becton, Dickinson and Company by 3.7% in the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 60 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Thomas E. Polen, Jr. sold 2,993 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $210.00, for a total transaction of $628,530.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $23,134,230. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 3,310 shares of company stock worth $688,650. Corporate insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on BDX shares. Wolfe Research initiated coverage on Becton, Dickinson and Company in a report on Tuesday, October 20th. They issued an “outperform” rating for the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $242.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, November 5th. TD Cowen lifted their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Finally, Barclays increased their price target on shares of Becton, Dickinson and Company from $165.00 to $195.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $197.47.

Check Out Our Latest Research Report on BDX

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $217.95 on Monday. The firm has a market cap of $60.05 billion, a P/E ratio of 52.64, a P/E/G ratio of 3.65 and a beta of 0.22. Becton, Dickinson and Company has a 52-week low of $140.11 and a 52-week high of $219.78. The business’s 50-day moving average price is $190.90 and its 200 day moving average price is $170.56. The company has a quick ratio of 0.54, a current ratio of 0.87 and a debt-to-equity ratio of 0.54.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, beating the consensus estimate of $4.07 by $0.08. The firm had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business earned $3.96 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 13.21 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback program on Thursday, November 5th that permits the company to repurchase 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 3.6% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be paid a $1.06 dividend. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date is Thursday, December 10th. This represents a $4.24 annualized dividend and a dividend yield of 1.9%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 101.45%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.